CYP17 Gene and Breast Cancer Risk
Author Information
Author(s): Kristjana Einarsdóttir, Tove Rylander-Rudqvist, Keith Humphreys, Susanne Ahlberg, Gudrun Jonasdottir, Elisabete Weiderpass, Kee Seng Chia, Magnus Ingelman-Sundberg, Ingemar Persson, Jianjun Liu, Per Hall, Sara Wedrén
Primary Institution: Karolinska Institutet
Hypothesis
Does the CYP17 c.1-34T>C polymorphism influence breast cancer risk in postmenopausal women?
Conclusion
CYP17 c.1-34T>C does not appear to have any major influence on breast cancer risk.
Supporting Evidence
- The study included a large sample size of 1,544 breast cancer cases and 1,502 controls.
- No overall association was found between the CYP17 polymorphism and breast cancer risk.
- An interaction with age at menarche was detected but considered a chance finding.
Takeaway
The study looked at a gene that might affect breast cancer risk but found that it doesn't really change the chances of getting breast cancer.
Methodology
The study genotyped 1,544 breast cancer cases and 1,502 controls for the CYP17 c.1-34T>C polymorphism using logistic regression models.
Potential Biases
Potential bias due to over-sampling of menopausal hormone users and diabetics.
Limitations
The study focused only on postmenopausal women, which may limit the generalizability of the findings.
Participant Demographics
All participants were postmenopausal Swedish women.
Statistical Information
P-Value
0.026
Confidence Interval
95% CI 0.8–1.3
Statistical Significance
p=0.026
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website